Names matter. Thrilled to share this Viewpoint we just published in The Lancet Haematology making the case that we should embrace the term 'Classical Hematology' over 'Benign' or Non-Malignant'. Honored to have written this with Drs. Alison Loren and Alfred Lee!

authors.elsevier.com/a/1e-2Z8MsWYC4…

New NEJM original article by Al-Samkari et al., 'Mitapivat versus Placebo for Pyruvate Kinase Deficiency' bit.ly/3JMSJNL Hanny Al-Samkari, MD

Congratulations to #MGH Hematologists Hanny Al-Samkari, MD Hanny Al-Samkari, MD, David J. Kuter, MD, and Rebecca Karp Leaf, MD Rebecca Karp Leaf, MD, who were included in the current issue of NEJM bit.ly/3MfErHa MassGeneral News

#MGH researchers, including lead author Hanny Al-Samkari, MD, have published the results of a clinical trial that led the U.S. FDA to recently approve mitapivat for the treatment of adults with #pyruvatekinasedeficiency . Learn more: bit.ly/3LccCiY MassGeneral News

Honored to share the results of ACTIVATE, the pivotal randomized phase 3 study leading to the FDA approval of mitapivat for pyruvate kinase deficiency, which we just published in the New England Journal of Medicine:
nejm.org/doi/full/10.10…

It's my pleasure to give a CDC Webinar on hereditary hemorrhagic telangiectasia with Dr. Raj Kasthuri on August 19! Check it out (and register) here! cdc.gov/ncbddd/blooddi…

Research led by Hanny Al-Samkari, MD and David Leaf found that among critically ill adults with #COVID19 , early therapeutic anticoagulation did not affect survival in the target trial emulation ow.ly/MNPQ50Dj1MC.

Critically ill #COVID19 patients have high risk of thromboembolism.

While waiting for randomized trials of therapeutic anticoagulation,

we emulated a #TargetTrial in ICU patients from STOP-COVID (observational study).

Little evidence of survival benefit
acpjournals.org/doi/10.7326/M2…

Great work Orly Leiva, MD plus Richard Newcomb and Hanny Al-Samkari, MD sorry to loose you to cardiology😀

How might we assess level of intervention for anemia in chronic bleeding disorders? A NEW letter to the editor at #RPTH suggests using a “hematologic support score” to quantify this. Learn what it means here: onlinelibrary.wiley.com/doi/full/10.10… Hanny Al-Samkari, MD Rakhi Naik, MD MHS

How can we consider RBC transfusions & iron infusions as a single endpoint for studies of chronic bleeding disorders, like HHT? The Hematologic Support Score (HSS) is proposed and detailed in this NEW letter from Hanny Al-Samkari, MD & Rakhi Naik, MD MHS - onlinelibrary.wiley.com/doi/full/10.10…

Check out a new episode of Clot Chronicles with
Hanny Al-Samkari, MD. He discusses new research on #bleeding and #thrombosis in #COVID19 . #Ddimer #anticoagulation tinyurl.com/yyp5zlfj

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection [Jul 23, 2020] Hanny Al-Samkari, MD et al. Blood Journal ow.ly/A9pU30r0fX6 #VTE #2019nCoV #COVID19 #CCC19 COVID-19 and Cancer Consortium (CCC19) Registry

ISTH presented us at #ISTH2020 a Late-Breaking Session on #COVID19 and related #VTE Lets summarize the findings:
1-Hanny Al-Samkari, MD from Massachusetts General Hospital CCCSEW presented data from 67 centers (3239) in US from #STOPCOVID 39,3% mortality - 28days. VTE seems not to impact mortality. Thread:

Great talk #ISTH2020 from Hanny Al-Samkari, MD on rate of #VTE and potential impact of full anticoagulation in pts w #COVID19 in ICUs.
VTE rate lower than other studies: 6.3%
Maj bleeding: 2.8%
No diff in survival in emulated trial population for full vs low heparin Rx.
#WeNeedTrials

Study by Hanny Al-Samkari, MD does not support emperic use of therapeutic #anticoagulation in critically ill patients with #Covid19 #isth2020 #thrombosis

Ongoing excellent presentations at ⁦ISTH⁩ 2020 meeting. Special shout out to ⁦Hanny Al-Samkari, MD⁩ who has 2 simultaneous platform presentations in bleeding and clotting!!!

In a new study, 108 patients with #ITP had plasma C3, C4, and CH50 measured. ⬇️ levels were a common feature & were associated with ⬆️ disease severity. Abraham Z. Cheloff, MD, MS & Hanny Al-Samkari, MD discuss results and highlight significance for clinical management: onlinelibrary.wiley.com/doi/full/10.10…

Complement contributes to #platelet destruction in immune thrombocytopenia but is poorly characterized. A new #RPTH study by Abraham Z. Cheloff, MD, MS and Hanny Al-Samkari, MD found reduced C3, C4, and/or CH50 in one-third of patients with #ITP vs healthy controls. onlinelibrary.wiley.com/doi/full/10.10…

Signed up for Twitter 8 years ago, and never once used it. January of 2021 and I'm tweeting for the first time. Well, better late than never!